MedTrace Logo

Pharmacokinetics of Ceftaroline in Normal and Obese Subjects

NCT01648127 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2013-03-14

No results posted yet for this study

Summary

The purpose of this study is to characterize plasma and urinary concentrations of ceftaroline following intravenous administration of a single dose of ceftaroline 600 mg in healthy subjects who are normal weight, overweight, and obese.

Conditions

  • Drug Safety

Interventions

DRUG

Ceftaroline

A single dose of ceftaroline fosamil 600 mg as a 1-hour continuous intravenous infusion

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • Keith A. Rodvold

    lead OTHER

Principal Investigators

  • Keith A Rodvold, Pharm.D. · University of Illinois at Chicago

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01648127 on ClinicalTrials.gov